$ABT (Abbott Laboratories)

$ABT {{ '2016-10-19T14:34:11+0000' | timeago}} • Webcast

$ABT gives a bullish outlook for its flash glucose monitoring system Libre, which is growing rapidly in Europe. The company expects it to do well in the US, also. In the foreseeable future, Libre can drive strong double-digit revenue growth, $ABT added.

$ABT {{ '2017-09-22T12:26:48+0000' | timeago}} • Announcement

$ABT got the FDA nod for magnetic resonance (MR)-conditional labeling for its implantable cardioverter defibrillators (ICD) and associated high voltage leads. The new MR-conditional labeling for the Ellipse ICD allows patients to undergo an MRI scan. Patients implanted with Ellipse device and Durata or Optisure leads can also undergo MRI scans.

$ABT {{ '2017-09-18T12:47:46+0000' | timeago}} • Announcement

$ABT is extending its previously announced tender offer to purchase all outstanding shares of Series B Convertible Perpetual Preferred Stock of Alere Inc. for $402 per share of Preferred Stock. The offer is being extended to allow additional time for the consummation of the merger, which is a condition to the completion of the offer.

$ABT {{ '2017-09-14T16:50:10+0000' | timeago}} • Announcement

$ABT BoD declared a quarterly common dividend of $0.265 per share. The dividend is payable Nov. 15, 2017, to shareholders of record at the close of business on Oct. 13, 2017.

$ABT {{ '2017-09-01T12:22:31+0000' | timeago}} • Announcement

$ABT said it is extending its tender offer to buy for cash all outstanding shares of Series B Convertible Perpetual Preferred Stock of Alere at $402 per share. The offer will now expire on Sept. 15, 2017.

$ABT {{ '2017-08-31T13:43:11+0000' | timeago}} • Announcement

$ABT said the Ministry of Health Labour and Welfare in Japan has granted national reimbursement for the FreeStyle Libre glucose monitoring system effective Sept. 1, 2017. The revolutionary system will be widely available to the more than 1MM Japanese people ages six and above with diabetes, both Type 1 and Type 2, on insulin therapy.

$ABT {{ '2017-08-30T16:14:21+0000' | timeago}} • Announcement

$ABT initiated U.S. pivotal clinical study evaluating safety and effectiveness of modified version of its Amplatzer device designed to correct common congenital heart defect that occurs in about 80,000 pre-term infants in the U.S. each year. Patent ductus arteriosus is a common heart defect, accounting for 5-10% of all congenital heart disease.

$ABT {{ '2017-08-30T16:03:53+0000' | timeago}} • Announcement

$ABT announced regulatory approval in Russia and the Netherlands for a new indication for its oral dydrogesterone medicine. Oral dydrogesterone, which has been used to treat progesterone insufficiency conditions, is now approved in these countries as treatment option to prepare uterus in women who undergo in vitro fertilization (IVF) treatment.

$ABT {{ '2017-08-29T16:14:25+0000' | timeago}} • Announcement

$ABT issued new updates for implanted cardiac devices. $ABT notified physicians of updates to its implantable pacemakers and defibrillators as part of its ongoing commitment to continuously improve patient care. The planned updates are designed to provide new patient management tools and further protection against unauthorized access.

$ABT {{ '2017-08-28T13:50:49+0000' | timeago}} • Announcement

$ABT designed the HeartMate 3 system to take LVAD therapy further. In developing the HeartMate 3 system, the company reduced the system's size while reimagining how blood passes through an LVAD. This system deploys Full MagLev technology to reduce trauma to the blood passing through the pump while optimizing blood flow.

$ABT {{ '2017-08-28T13:35:49+0000' | timeago}} • Announcement

$ABT received U.S. FDA approval for its Full MagLev HeartMate 3 Left Ventricular Assist System (LVAD). The HeartMate 3 system provides a new option for physicians managing advanced heart failure patients in need of short-term hemodynamic support and provides patients living with their device new benefits that embody the evolution of LVAD therapy.

$ABT {{ '2017-08-15T12:37:58+0000' | timeago}} • Announcement

North West London Pathology (NWLP) and $ABT signed a $252MM managed equipment services contract for the supply of all analytical equipment and consumables. This includes $ABT's Alinity ci and Alinity h series diagnostics instruments as well as their professional services and informatics solutions known as AlinIQ.

$ABT {{ '2017-08-14T12:19:03+0000' | timeago}} • Announcement

$ABT said it is extending its tender offer to purchase for cash all outstanding shares of Series B Convertible Perpetual Preferred Stock at a price of $402 per share. The Offer was previously scheduled to expire on Aug. 11, 2017 and will now expire on Aug. 31, 2017.

$ABT {{ '2017-07-25T15:58:08+0000' | timeago}} • Announcement

$ABT has announced that the first patient has been enrolled in a clinical study evaluating the short-term use of common blood thinning medicines, called dual antiplatelet therapy (DAPT), after receiving a Xience everolimus-eluting coronary stent to unblock coronary arteries. Approx 2,000 patients at 100 sites in the US and Asia will be studied.

$BIIB {{ '2017-07-25T14:47:25+0000' | timeago}} • Announcement

$BIIB, which competes with $ABT and $PFE, posted record 2Q17 revenue, on strong Spinraza demand in the US, though YoY profit fell 18% on higher expenses. Net earnings attributable to Biogen plunged to $862.8MM, while diluted EPS fell 15.03% to $4.07. Revenue, however, jumped 6% to $3.1Bil. $BIIB lifted its outlook due to strong Spinraza sales.

$ABT {{ '2017-07-20T19:55:45+0000' | timeago}} • Webcast

For 3Q17, $ABT expects adjusted EPS of $0.64-0.66, with operational sales growth expected in the mid-single digits. At current exchange rates, the company expects operational sales growth to have a negative YoY impact of around 0.5%.

$ABT {{ '2017-07-20T19:45:56+0000' | timeago}} • Webcast

$ABT said that on a comparable operational basis, 3Q17 Established Pharmaceuticals sales growth is expected in the high double-digit, while in Nutrition, sales growth is expected in low single-digit. In Diagnostics, $ABT expects sales to increase mid-to-high single digits and in Medical Devices, sales is expected to increase double-digits.

$ABT {{ '2017-07-20T17:49:19+0000' | timeago}} • Announcement

$ABT raised its full year profit forecast backed by the intention of closing the Alere acquisition in 2017. The company raised its FY17 adjusted earnings from continuing operations guidance by $0.03 to a range of $2.43-2.53 per share. Reported EPS forecast was also raised from the range of $0.92-1.02 to $1.03-1.13, reflecting double-digit growth.

$ABT {{ '2017-07-20T17:36:53+0000' | timeago}} • Announcement

Declining operating earnings and rising costs and expenses hit $ABT 2Q17 earnings as much as 54%. Earnings plunged to $283MM or $0.15 from $615MM or $0.40 per share a year earlier. Sales, however, surged 24.4% on St. Jude Medical acquisition. On an adjusted basis, $ABT reported EPS above its previous guidance range at $0.62 per share.

$ABT {{ '2017-07-20T12:52:57+0000' | timeago}} • Infographic

$ABT Abbott Laboratories Earnings AlphaGraphic: Q2 2017 Highlights

$ABT {{ '2017-07-17T12:36:21+0000' | timeago}} • Announcement

$ABT is commencing a tender offer to purchase for cash all outstanding shares of Series B Convertible Perpetual Preferred Stock of Alere Inc. at a price of $402 per share of Preferred Stock. The offer will expire at 11:59 pm, NYC time, on Aug 11, 2017. There is no financing condition to the offer.

Recent Transcripts

LCI (Lannett Company, Inc.)
Wednesday, August 23 2017 - 8:30pm
MDT (Medtronic plc)
Tuesday, August 22 2017 - 12:00pm
VRML (Vermillion, Inc.)
Wednesday, August 9 2017 - 8:30pm
LIVN (LivaNova PLC)
Wednesday, August 9 2017 - 1:00pm
IVC (Invacare Corporation)
Tuesday, August 8 2017 - 12:30pm
MNK (Mallinckrodt Public Limited Company)
Tuesday, August 8 2017 - 12:30pm
KND (Kindred Healthcare Inc.)
Friday, August 4 2017 - 1:00pm
CBM (Cambrex Corporation.)
Friday, August 4 2017 - 12:30pm
EBS (Emergent BioSolutions, Inc.)
Thursday, August 3 2017 - 9:00pm
CYTK (Cytokinetics, Incorporated)
Wednesday, August 2 2017 - 8:30pm
PCRX (Pacira Pharmaceuticals, Inc.)
Wednesday, August 2 2017 - 12:30pm
MD (MEDNAX, Inc.)
Friday, July 28 2017 - 2:00pm
MRK (Merck & Co. Inc.)
Friday, July 28 2017 - 12:00pm
ABAX (Abaxis, Inc.)
Thursday, July 27 2017 - 8:15pm
BMY (Bristol-Myers Squibb Company)
Thursday, July 27 2017 - 2:30pm
RDY (Dr. Reddy's Laboratories Ltd.)
Thursday, July 27 2017 - 1:00pm
MCK (McKesson Corporation)
Thursday, July 27 2017 - 12:30pm
INVA (Innoviva, Inc.)
Wednesday, July 26 2017 - 9:00pm
GILD (Gilead Sciences Inc.)
Wednesday, July 26 2017 - 8:30pm
GSK (GlaxoSmithKline plc)
Wednesday, July 26 2017 - 1:00pm

AlphaGraphics you may like